---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-031085"
form_type: "8-K"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:32:12.465930+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Atossa Therapeutics appoints Jonathan Finn to board of directors and audit committee

## Summary
- Jonathan Finn appointed to board as Class I director and audit committee member, effective November 9, 2023.
- Finn succeeds Greg Weaver and will serve until the 2025 Annual Meeting of Stockholders.
- Finn brings over 25 years of financial industry experience, focusing on early to mid-stage biotech and tech companies.
- Compensation follows standard non-employee director terms as per 2023 proxy; standard indemnification agreement to be entered.
- No arrangements, family relationships, or material interests in any transactions requiring disclosure.

## SEC filing metadata
- accession: 0001437749-23-031085
- form_type: 8-K
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000143774923031085/0001437749-23-031085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000143774923031085/atos20231106_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-031085
- JSON: https://secwatch.observer/filing/0001437749-23-031085.json
- Plain text: https://secwatch.observer/filing/0001437749-23-031085.txt

## Key facts
- Executive change
  Jonathan Finn was appointed as Class I Director at ATOSSA THERAPEUTICS, INC..
  - Action: appointed
  - Role: Class I Director
  source text: Jonathan Finn, CFA, has been appointed to the Company's board of directors, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1488039/000143774923031085/0001437749-23-031085-index.htm
- Executive change
  Greg Weaver departed as Class I Director at ATOSSA THERAPEUTICS, INC..
  - Action: succeeded
  - Role: Class I Director
  source text: Mr. Finn succeeded Greg Weaver as a Class I director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1488039/000143774923031085/0001437749-23-031085-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.